Key Points
- Nuvalent insider Deborah Ann Miller sold 5,500 shares on May 28 at an average price of $107.84, totaling about $593,120. After the sale, she still held 59,634 shares, a reduction of 8.44% in her ownership.
- This was not her first recent sale: Miller also sold 5,500 shares on April 30 at an average price of $99.22, for about $545,710.
- Nuvalent recently missed quarterly earnings estimates, reporting EPS of -$1.39 versus the expected -$1.35. Despite mixed fundamentals and a share price below its 50-day and 200-day moving averages, analysts still broadly rate the stock a Moderate Buy.
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider directly owned 59,634 shares of the company's stock, valued at $6,430,930.56. This trade represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Deborah Ann Miller also recently made the following trade(s):
- On Thursday, April 30th, Deborah Ann Miller sold 5,500 shares of Nuvalent stock. The stock was sold at an average price of $99.22, for a total value of $545,710.00.
Nuvalent Price Performance
Shares of NUVL stock opened at $93.01 on Tuesday. The stock has a 50-day moving average of $102.94 and a 200-day moving average of $103.29. The stock has a market cap of $7.35 billion, a PE ratio of -15.35 and a beta of 1.15. Nuvalent, Inc. has a one year low of $71.13 and a one year high of $113.01.
Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.04). During the same quarter last year, the company posted ($1.18) EPS. As a group, research analysts anticipate that Nuvalent, Inc. will post -5.74 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on NUVL shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nuvalent in a research report on Tuesday, April 21st. Wells Fargo & Company began coverage on Nuvalent in a report on Monday, March 30th. They set an "overweight" rating and a $116.00 price target for the company. Sanford C. Bernstein initiated coverage on Nuvalent in a report on Thursday, May 21st. They set an "outperform" rating and a $189.00 target price on the stock. Cantor Fitzgerald increased their price objective on shares of Nuvalent from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Friday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $155.00 price objective on shares of Nuvalent in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $140.29.
Check Out Our Latest Stock Report on Nuvalent
Hedge Funds Weigh In On Nuvalent
Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its position in Nuvalent by 64.8% in the first quarter. AQR Capital Management LLC now owns 9,874 shares of the company's stock valued at $700,000 after purchasing an additional 3,881 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company's stock valued at $32,171,000 after acquiring an additional 159,873 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Nuvalent by 8.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company's stock valued at $10,634,000 after purchasing an additional 12,123 shares during the period. Intech Investment Management LLC raised its holdings in Nuvalent by 28.7% during the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company's stock worth $1,366,000 after buying an additional 4,293 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Nuvalent in the 2nd quarter worth about $412,000. 97.26% of the stock is currently owned by institutional investors and hedge funds.
About Nuvalent
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
